Archive
Home / Media Centre / Archive
Here you can find the archive of all Press Releases prior to 2023
Filter by date:
Showing 1239 press releases before 2023
-
Evusheld long-acting antibody combination approved in the EU for the treatment of COVID-19
-
Beyfortus (nirsevimab) recommended for approval in the EU by CHMP for the prevention of RSV lower respiratory tract disease in infants
-
Danicopan (ALXN2040) add-on to Ultomiris or Soliris met primary endpoint in ALPHA Phase III trial for patients with paroxysmal
-
Evusheld long-acting antibody combination recommended for approval in the EU for the treatment of COVID-19
-
Imfinzi plus chemotherapy further improved overall survival benefit in advanced biliary tract cancer in the TOPAZ-1 Phase III trial, reducing the risk of death by 24% in additional follow-up
-
Imfinzi and tremelimumab with chemotherapy demonstrated sustained survival benefit in metastatic non-small cell lung cancer, nearly doubling the number of patients alive after three years vs. chemotherapy
-
Enhertu continues to demonstrate clinically meaningful tumour response in patients with HER2-mutant metastatic non-small cell lung cancer
-
Tagrisso demonstrated 5.5-year median disease-free survival in the adjuvant treatment of patients with EGFR-mutated lung cancer
-
Lynparza in combination with bevacizumab, and as a monotherapy, demonstrates clinically meaningful survival benefit in 1st-line advanced ovarian cancer across two Phase III trials
-
Forxiga approved in China for the treatment of chronic kidney disease in patients at risk of progression with and without type-2 diabetes
Latest articles and press releases
All of our latest press releases and articles are available to explore
